Product Description
Mezagitamab is a fully human immunoglobulin (Ig) G1 monoclonal antibody with high affinity to CD38 that depletes tumor cells expressing CD38 by antibody- and complement-dependent cytotoxicity. CD38 is a cell surface molecule that is highly expressed on myeloma cells, plasma cells, plasmablasts, and natural killer (NK) cells, and is induced on activated T cells and other suppressor cells including regulatory T (Tregs) and B (Bregs) cells. (Sourced from: https://ashpublications.org/blood/article/136/Supplement%201/9/469909/Mezagitamab-Induces-Immunomodulatory-Effect-in)
Mechanisms of Action: CD38 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Bulgaria, Canada, China, Croatia, Germany, Greece, Hungary, Italy, Japan, Korea, Poland, Serbia, Singapore, Slovenia, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia
Phase 2: Multiple Myeloma|Muscle Weakness|Myasthenia Gravis
Phase 1: Glomerulonephritis|IgA Nephropathy|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TAK-079-3002 | P3 |
Not yet recruiting |
Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia |
2028-01-03 |
|
| TAK-079-1006 | P1 |
Active, not recruiting |
Glomerulonephritis|Kidney Diseases |
2026-03-23 |
|
| jRCT2011220009 | P1 |
Active, not recruiting |
Kidney Diseases|Glomerulonephritis |
2026-03-23 |
|
| TAK-079-1002 | P1 |
Active, not recruiting |
Multiple Myeloma |
2025-02-23 |
48% |